- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about CHRS
Recent news which mentions CHRS
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session
December 29, 2022
From Benzinga
Tesla, NIO And Some Other Big Stocks Moving Lower On Tuesday
December 27, 2022
From Benzinga
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
December 27, 2022
From Benzinga
Why DBV Technologies Shares Are Trading Higher By 38%; Here Are 26 Stocks Moving Premarket
December 23, 2022
From Benzinga
Mirati Plays Catch-Up With Amgen, Gilead's 2nd Try With AIDS Drug, Cytokinetics' Adcom Test And More: Key Nov FDA Decisions For Biotech Investors
December 02, 2022
From Benzinga
Looking Into Coherus BioSciences Return On Capital Employed
August 17, 2022
Tickers
CHRS
From Benzinga
Coherus BioSciences (CHRS) Q2 2022 Earnings Call Transcript
August 06, 2022
Tickers
CHRS
From Motley Fool
From Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
August 03, 2022
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Thursday
June 02, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
June 01, 2022
From Benzinga
From Benzinga
Tickers
CHRS
From Motley Fool
From Benzinga
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
April 20, 2022
From Benzinga
7 Biotech Stocks to Buy With Key Catalysts for April
April 05, 2022
From InvestorPlace
From Benzinga
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
March 15, 2022
Tickers
CHRS
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.